A nasal allergy test showed strong diagnostic performance, with sensitivity exceeding 75% and specificity approaching 90% for detecting allergens sensitized in patients with allergic rhinitis.

It’s allergy season, and that means stuffy noses and congestion are back. It's a feeling we can't escape. We want relief anywhere we can find it, sometimes resorting to acupuncture, a neti pot, or ...

The changing of seasons is often accompanied by undesirable side effects known as seasonal allergies. Seasonal allergies plague many people due to the sudden presence of specific plant pollen that ...

Local nasal immunotherapy (LNIT) safely improves clinical symptoms, reduces medication use, and increases the nasal provocation threshold for patients with allergic rhinitis, according to results of a ...

The incidence of provider-diagnosed AR in the United States is approximately 60 million people, including both adults and children. 2 The incidence is even higher when patients self-report AR: between ...

Spring is in the air, the days are getting longer and warmer... but for millions of Americans it’s dreaded allergy symptoms that are in full bloom. And if you’re one of them, you may be desperately ...

The first non-injectable emergency treatment for allergies is anticipated to hit shelves following FDA approval of the neffy epinephrine nasal spray. The product from ARS Pharmaceuticals, previously ...

During the meeting, Polyrizon presented the general development program plan for PL-14, including the proposed manufacturing process, analytical and quality controls, and the structure of the ...

Physicians and patients deemed real-world use of neffy epinephrine nasal spray effective and easy, according to data ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Astepro® Allergy (Azelastine HCI .15%) as an over-the-counter (OTC) product for the ...

ReBoost Nasal Spray, sold nationwide, has been recalled due to potential mold and microbial contamination. Here’s what we ...